Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sport19 I think McNally was speaking directly to you when he explained the reason for the recent delays
Just have to be patients and conscious
Great insight moose! Side note this is also a reason using book value is problematic for tech firm valuations. You're right there's a lot of noise here with no knowledge behind it, just negativity.
Human studies coming soon! IDE request in the hopper!
It would be GREAT to see TMDI follow suit. No pun intended. Once they are cash flow positive. actions have consequences. Think before you post. Defamation is no joke.
Also glg said more partner news next week. Seldom is he wrong about this stuff...exciting to see what comes of it!
Great find. Makes perfect sense...this is what I suspected....BS.
Im calling bs. This is a "anyone can submit" format and there's only one complaining about a PIPE hedging tactic that's vastly employed in private funds. It offers no evidence and is contrary to the statement on their site about their long position strategy. It's some upset investor who doesnt like private equity. Cry me a river.
Its just your O though. You have no proof that they knowingly and intentionally falsified their forward looking statements. Let us know if you uncover something. Until then, I am not going to make that leap. I chalk it up to the rigors of development. I can imagine there's a lot of nuance and unexpected issues that arise. Bottom line it appears we truly are close to the finish line this time. If 2022 rolls around and no sales I will join the lather rinse repeat squad. Mark it down, Sammy!
Life lesson - fairness is when you get what you want (on the basis that you simply want it or feel some entitlement). Justice/equity is when you get what you deserve. All of us who invested in the secondary market in this company did so at our own peril and without any promises from the company. Therefore, it is still equitable if your return is rotten. You assumed the risk. "Fair" does not exist in the lexicon of mature individuals.
I'd argue the primary fiduciary obligation of an R&D company is to deliver shareholder value through commercializing a saleable asset. Different than a cash flowing company. Get to market vs grow market share. That said, it's better to deliver a product to the market with a higher chance of success delayed than to put out a product with less chance of success but on time. Based on the wells fargo presentation it seems the reasons for this delay will increase the probability of regulatory clearance and thus well worth it. I'd argue the diligence in delivering the best possible product to market is the greater act of fiduciary responsibility in this instance.
I understand the frustration...more of the same and all that. I remain optimistic.
Trxc is not long for this world. Within a year they will likely be selling for scrap.
Titan has 100+ global patents / applications per corporate presentation
It's only 100k shares more than 1 month ago, so no. If they were employing that strategy they would need to short 1.77+ million shares (equivalent to long pipe position). If we see that many added to short volume in the near future here you may have a case. Otherwise no, sir.
There's a Hedging stategy where a firm buys a PIPE on the cheap and agrees not to sell until a given point (a year is common) and simultaneously shorts the current market shares locking in the variance. It's smart - No matter where the price goes in that year they've locked in that profit (unless price goes way out of range and causes margin call for short positions - not expected, though). Since aspire capital states they are long only, we know they are not playing the stock and belive it will appreciate. Yipee! Good things happening in light of the recent delay. The more long only PIPEs we can use to fund without dilution the better...well played mgmt!
Because aspire capital are liars right?
Nothing is impossible, mangosteen.
Youre probably right....I can wait a year and a half
Nah reality is how I orient myself. I know that I don't know everything and I make no bones about the risk I decided to take with this long investment...no sour grapes here...you've got a 40 acre Vineyard full brosef. Try glass half full for a change...you'll live longer.
Having come this far, + 1 Q is peanuts to me if they can pull it off. I said from the first utterance of that submission target I thought it was overly optimistic. Just the nature of FDA, takes long tai.
He moved the ball from Q3 to Q4. Big whoop. What bothers me is the insinuation they are going to tinker some more, thought DF was in place - they should offer clarification there. If they make changes, could that not mean they need to re-do some studies? I hope it's not listening to surgeons ideals of how the robot should work still ..after the years and years of tinkering. Get out the commercial product and release upgrades later. Let's roll Titan! Err... let's finish enos!
U have link?
Nightmare on Helen Street
Do you know if this is class II or III? I'm assuming II since there's been no mention of PMA and all 510k - which means it's relatively LESS difficult since it's not a life sustaining device and you are basing your application a predicate device - which could only be Intuitive SP.
Not everyone brother.
Agreed
How can one explain the exclusive deal with teleflex for lig clips? Covidien wouldn't allow that.
Watch out for the windmill. Timing is everything
I am aware and I believe the surgeons were happy with the performance. However, Titan scaled back the initial indications to gyn and i believe some general surgeries, so why would they be performing cases in the last few months that could not be used as a basis for fda submission?
I dunno it would be nice if the presser was less vague about the changes yet to be made. I thought we had hardware DF locked down? The ambiguity in the presser does hint at larger forces at play as others have pointed out...perhaps a glass half full view of the news.
I'm among the most hopeful and optimistic that SPORT will end well, and I've reiterated many of the MDT coincidences. But in your assesment you quote MDT leadership stating their robot was used on a partial nephtectomy recently. SPORT is gunning for GYN indications only up front (correct me if I've missed something), so it seems that admission rules out MDT as the suitor. I also cannot resolve how MDT would allow exclusivity with teleflex for ligation clips when they sell their own through covidien. Are they going it alone - who knows, there are a lot of good points that suggest solo and partnership. The only absolute evidence we have is what TMDI has said, which is solo.
That's a good thought, it would certainly comport with ISRG's strategy
A deal as in the shelf offering or a deal as in a partnership deal?
Thanks SW - I am not as keen on the M&A game, that makes sense. I really really want it to be MDT but if I was giving paid opinion I would agree there's no silver bullet to tie all the coincidences together yet. It's exciting to know the coincidences are out there, if not just for a glimmer of hope.
Great to hear from you again! It's hard to ignore all the evidence. I hope it is MDT on 9/24 but prepared for it not to be. Also I thought they didn't specify whether the big release was single or multi port? Maybe I am not remembering that correctly.
I was not aware they both used Knobbe Marten...i know you've talked about that before I must have missed that. Just ANOTHER among the many many coincidences.
I agree approval is most likely required before acquisition. I've always said sp will not be fun until years of proven sales. However everytime I think I know how businesses think, I am surpsied. If considering an acquisition of TMDI, are you sure MDT would be preoccupied with past dilutions rather than how they can leverage the technology into the future? Sounds more like sour grapes about dilution. Not all robots have had years of sales growth before acquisition...Auris was on the market for 11 months before jnj swooped in.
NICE find! This confirms (sort of) that the Covidien robotic is/was called Einstein (see patent comment on chart p 18 )....ENOS?!
Also the article gives away some detail about the covidien robot...that its a bedside mount 3 arm....
You're right but a justia search for "covidien robot" does not turn up many results....mostly wrist and jaw devices...end effector? Also training software. Enough to build their own robot on top of the expired davinci patents?
https://patents.justia.com/search?q=Covidien+robot
Forgot to mention....no MDT IP portfolio for the robot....compared to titan...that's the real puzzler